ABBV Overview
Upcoming Projects (ABBV)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ABBV)
-
Discussing the AMPLIFY Phase III trial of Calquence plus venetoclax as a first line treatment for chronic lymphocytic leukemia
Tickers: AZN, ABBV, RHHBY
Executed On: Aug 29, 2024 at 12:00 PM EDT -
Quarterly Survey: Breast Augmentation Procedures and Implant Preferences July 2024
Tickers: ABBV, ESTA, JNJ, SIEN
Executed On: Jul 26, 2024 at 12:24 PM EDT -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify July 2024
Tickers: RVNC, ABBV, EOLS, Galderma, Merz Aesthetics
Executed On: Jul 26, 2024 at 12:20 PM EDT -
Examining the market potential of AbbVie's EPKINLY® (epcoritamab-bysp) for relapsed/refractory follicular lymphoma
Ticker: ABBV
Executed On: Jul 17, 2024 at 11:00 AM EDT -
A Second Opinion: Understanding the latest updates and clinical development trends in SCLC from ASCO 2024
Tickers: AMGN, ABBV, GSK, MRK
Executed On: Jun 20, 2024 at 02:30 PM EDT -
Understanding the latest updates and clinical development trends in SCLC from ASCO 2024
Tickers: AMGN, ABBV, GSK, MRK
Executed On: Jun 12, 2024 at 11:00 AM EDT -
Quarterly Survey: Breast Augmentation Procedures and Implant Preferences April 2024
Tickers: ESTA, ABBV, JNJ, SIEN
Executed On: May 01, 2024 at 11:05 AM EDT -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify April 2024
Tickers: RVNC, ABBV, EOLS, Galderma, Merz Aesthetics
Executed On: Apr 18, 2024 at 12:52 PM EDT -
A discussion of BTK inhibitors in Chronic Lymphocytic Leukemia, including zanabrutinib and NX-5948
Tickers: BGNE, ABBV, NRIX
Executed On: Jan 26, 2024 at 02:00 PM EST -
Quarterly Survey: Breast Augmentation Procedures and Implant Preferences January 2024
Tickers: ESTA, ABBV, JNJ, SIEN
Executed On: Jan 24, 2024 at 12:43 PM EST -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify January 2024
Tickers: RVNC, ABBV, EOLS, Galderma, Merz Aesthetics
Executed On: Jan 19, 2024 at 10:48 AM EST -
Investigating the potential of two oral JAK inhibitors, Rinvoq (upadacitinib) from Abbvie and Povorcitinib (INCB54707) from Incyte Bio as treatments for non-segmental vitiligo.
Tickers: ABBV, INCY
Executed On: Nov 22, 2023 at 08:30 AM EST -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify October 2023
Tickers: RVNC, ABBV
Executed On: Oct 31, 2023 at 12:02 PM EDT -
Quarterly Survey: Breast Augmentation Procedures and Implant Trends/Preferences October 2023
Tickers: ABBV, JNJ, SIEN, ESTA
Executed On: Oct 31, 2023 at 11:28 AM EDT -
Quarterly Survey: Breast Augmentation Procedures and Implant Trends/Preferences July 2023
Tickers: ABBV, JNJ, SIEN, ESTA
Executed On: Aug 02, 2023 at 10:52 AM EDT -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify July 2023
Tickers: RVNC, ABBV, IPN, EOLS
Executed On: Jul 31, 2023 at 03:46 PM EDT -
Examining the topline results from the Phase 2b FRONTIER 1 clinical trial of Johnson & Johnson's JNJ-2113 in patients with Plaque Psoriasis.
Tickers: JNJ, ABBV
Executed On: Jul 13, 2023 at 11:00 AM EDT -
A Second Look: Discussing CD20xCD3 Bispecifics in DLBCL, with a focus on glofitamab & Epcoritamab
Tickers: ABBV, RHHBY
Executed On: Jul 12, 2023 at 11:00 AM EDT -
Discussing CD20xCD3 Bispecifics in DLBCL, with a focus on glofitamab & Epcoritamab
Tickers: ABBV, RHHBY
Executed On: Jul 06, 2023 at 05:00 PM EDT -
Delving into the data from the SLEek clinical trial on Abbvie's RINVOQ (upadacitinib) in treating patients with Systemic Lupus Erythematosus.
Ticker: ABBV
Executed On: Jun 06, 2023 at 03:15 PM EDT -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify April 2023
Tickers: RVNC, ABBV, IPN
Executed On: Apr 19, 2023 at 12:15 PM EDT -
Quarterly Survey: Breast Implants April 2023
Tickers: JNJ, SIEN, ABBV
Executed On: Apr 14, 2023 at 03:38 PM EDT -
Quarterly Survey: Frown Line Treatments with a focus on Revance's Daxxify January 2023
Tickers: RVNC, ABBV, IPN
Executed On: Feb 14, 2023 at 12:43 PM EST -
Quarterly Survey: Breast Implants February 2023
Tickers: JNJ, SIEN, ABBV
Executed On: Feb 07, 2023 at 06:12 PM EST
Expired Projects (ABBV)
-
A Look at Novartis' Cosentyx in treating Hidradenitis Suppurativa and how it can compete with Humira
Tickers: NVS, ABBV, ANAB
Execute By: Aug 08, 2022 -
Evaluating the Multiple Sclerosis Market After AbbVie (ABBV) and Biogen (BIIB) Receive CHMP Support for EU Approval of Zinbryta
Tickers: ABBV, BIIB, TEVA, NVS, SNY, MedDay Pharmaceuticals, RHHBY
Execute By: May 23, 2016
Upcoming & Overdue Catalysts (ABBV)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ABBV)
-
Rova-T (TRINITY) Phase 2 pivotal data in Third-line Small Cell Lung Cancer expected Q4 2017
Ticker: ABBV
Occurred on: Mar 22, 2018 -
Phase 3 Topline data of Neurocrine's (NBIX) Elagolix in treating Uterine Fibroids expected Q1 2018
Tickers: NBIX, ABBV
Occurred on: Feb 21, 2018 -
Abbvie's(ABBV) Upadacitinib (ABT-494) as Monotherapy Results released in Phase 3 Rheumatoid Arthritis Study
Ticker: ABBV
Occurred on: Dec 20, 2017 -
Phase 3 data of AbbVie's(ABBV) Risankizumab in Psoriasis due by the end of 2017 due by the end of 2017
Ticker: ABBV
Occurred on: Oct 26, 2017 -
NDA for Elagolix in treating Endometriosis anticipated in 3rd Quarter 2017
Tickers: ABBV, NBIX
Occurred on: Sep 06, 2017 -
AbbVie/Enata Hepatitis C Drug, Glecaprevir/Pibrentasvir (G/P), PDUFA Approximately 8/2/2017
Tickers: ABBV, ENTA
Occurred on: Aug 03, 2017 -
Data available 2H from Phase III study of Empliciti in first-line multiple myeloma
Tickers: BMY, ABBV
Occurred on: Jun 24, 2017 -
AbbVie commences Phase 3 trial of ABT-494 for rheumatoid arthritis, expected completion mid-2017
Ticker: ABBV
Occurred on: Jun 07, 2017 -
AbbVie (ABBV) Phase 2 Data Evaluating ABT-494 in Crohn's Disease Expected in H1 2017
Ticker: ABBV
Occurred on: May 09, 2017 -
Dr. Reddy (RDY) Launches Generic Version of AbbVie's (ABBV) Prometrium (Progesterone USP) in U.S
Tickers: RDY, ABBV
Occurred on: Apr 25, 2017 -
AbbVie (ABBV) Reports Data Phase 3 Data Evaluating Veliparib in Non-Small Cell Lung Cancer and Triple Negative Breast Cancer
Ticker: ABBV
Occurred on: Apr 19, 2017 -
AbbVie's Main US Patent on HUMIRA (adalimumab) to expire in December 2016, Still Protected by Dozens of Other Patents
Ticker: ABBV
Occurred on: Dec 31, 2016 -
Boehringer Ingelheim Announces Phase 3 Results for Humira Biosimilar Candidate in Active Rheumatoid Arthritis
Tickers: BOEHRINGER INGELHEIM, ABBV
Occurred on: Oct 26, 2016 -
AbbVie (ABBV) Presents Data From Two Phase 3 Trails Evaluating Elagolix in Premenopausal Women with Endometriosis
Ticker: ABBV
Occurred on: Oct 19, 2016 -
FDA Announces Black Box Requirement for Risk of HBV Reactivation for at Least 9 Brand Name Drugs in Hepatitis C Treatment
Tickers: GILD, ABBV, MRK
Occurred on: Oct 05, 2016 -
AbbVie's (ABBV) Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
Ticker: ABBV
Occurred on: Sep 30, 2016 -
AbbVie files patent lawsuit seeking to stop Amgen’s copy of Humira
Tickers: ABBV, AMGN
Occurred on: Aug 05, 2016 -
AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
Ticker: ABBV
Occurred on: Jul 28, 2016 -
Biogen and AbbVie’s Once-Monthly ZINBRYTA (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis
Tickers: BIIB, ABBV
Occurred on: Jul 05, 2016 -
Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA (daclizumab) for Multiple Sclerosis
Tickers: ABBV, BIIB
Occurred on: May 27, 2016 -
EMA Decision on Regulatory Filings for Empliciti for Approval in Europe Due by April 1
Tickers: BMY, ABBV
Occurred on: May 11, 2016 -
FDA Priority Review date for Venetoclax Set mid-2016
Ticker: ABBV
Occurred on: Apr 11, 2016 -
U.S. FDA Approves IMBRUVICA (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia
Tickers: JNJ, ABBV, Janssen Biotech
Occurred on: Mar 04, 2016 -
IMBRUVICA (ibrutinib) Approved by U.S. FDA for the First-line Treatment of Chronic Lymphocytic Leukemia
Ticker: ABBV
Occurred on: Mar 04, 2016 -
AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)
Ticker: ABBV
Occurred on: Feb 26, 2016 -
AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis
Ticker: ABBV
Occurred on: Feb 10, 2016 -
AbbVie and Roche's venetoclax gets new Breakthrough Therapy tag for blood cancer
Tickers: ABBV, SWX: RO
Occurred on: Jan 20, 2016 -
Lilly (LLY) Announces Positive Phase 3 SPIRIT-P1 Data Evaluating Ixekizumab in Patients With Psoriatic Arthritis
Tickers: LLY, ABBV
Occurred on: Nov 08, 2015
Strategic Initiatives (ABBV)
-
AbbVie (ABBV) and I-Mab (IMAB) Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
Tickers: ABBV, IMAB
Announcement Date: Sep 04, 2020 -
FTC has voted 3-1-1 approving a final order settling charges that AbbVie's (ABBV) $63B takeover of Allergan (AGN) would violate federal antitrust law
Ticker: ABBV
Announcement Date: Sep 04, 2020 -
AbbVie (ABBV) Agrees to Collaborate with BioArtic to Develop Treatments for Neurodegenerative Diseases Including Parkinson's
Tickers: ABBV, BioArtic
Announcement Date: Sep 20, 2016 -
X-Chem and AbbVie Enter into Multi-Target Drug Discovery Partnership
Tickers: ABBV, X-Chem
Announcement Date: Jul 26, 2016 -
AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen
Tickers: BMY, ABBV
Announcement Date: Jul 25, 2016 -
AbbVie buys Stemcentrx and its Novel, Late-Stage Rova-T Compound for Small Cell Lung Cancer
Ticker: ABBV
Announcement Date: Apr 28, 2016 -
AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
Tickers: ABBV, Boehringer Ingelheim
Announcement Date: Mar 07, 2016 -
Philogen announces expanded research and development agreement with Abbvie
Tickers: ABBV, Philogen S.p.A.
Announcement Date: Feb 15, 2016